Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug curb ice addiction? new trial aims to find out

NCT ID NCT07509112

Disease control Sponsor: Kirby Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial will test whether semaglutide, the drug in Ozempic, can help people with methamphetamine use disorder cut down their use. Forty adults who use methamphetamine at least 14 days per month will receive weekly injections for 12 weeks. The study will check if the treatment is safe and practical, and whether it reduces methamphetamine use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (Ozempic)
What this could lead to
If it works, this could point toward a new treatment option for methamphetamine use disorder, helping people cut down or stop using the drug.
What could go wrong
This is a very small, early-phase trial with only 40 people. It is designed mainly to test safety and practicality, not to prove effectiveness. The results may not apply to everyone, and the drug may not reduce methamphetamine use at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Has provided voluntary, written informed consent; 2. Aged 18 years or older; 3. Diagnosed with moderate to severe methamphetamine use disorder (DSM-5 criteria); 4. Self-reported methamphetamine use on at least 14 of past 28 days and a positive oral fluid drug screen for amphetamine/methamphetamine; 5. Willing and able to comply with study procedures and follow-up visits; 6. People of child-bearing potential must agree to use effective contraception during treatment and during the 60 days after treatment end. Exclusion Criteria: 1. Uncontrolled medical or psychiatric conditions that may interfere with participation; 2. Body mass index less than 22 kg/m2; 3. Confirmed diagnosis of diabetes mellitus (either known history of diabetes; concomitant treatment with insulin, metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitor, DPP4 inhibitor; or HbA1c \>6.5 at screening); 4. Currently taking a GLP-1 receptor agonist; 5. Known hypersensitivity or contraindications to GLP-1 receptor agonists as per product information; 6. Current enrolment in another interventional trial; 7. Lactating, pregnant or at risk of pregnancy not willing to avoid pregnancy 8. History of pancreatitis; 9. History of medullary thyroid cancer; 10. Current admission to a residential rehabilitation program or inpatient program or planned admission during the study period, which would interfere with participation in study visits or procedures; 11. Currently experiencing psychosis or current active suicidality 12. Any condition or circumstance that, in the opinion of the investigator, would compromise the participant's ability to comply with the study procedures, complete protocol requirements, or provide reliable data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Methamphetamine use disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behavior, Addictive methamphetamine dependence substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Methamphetamine use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    5 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Alcohol & Drug Service, Metro Health North Brisbane

    Brisbane, Queensland, 4000, Australia

  • Drug and Alcohol Services, South Australia

    Morphett Vale, South Australia, 5162, Australia

  • Kirketon Road Centre

    Darlinghurst, New South Wales, 2010, Australia

  • Next Step Drug and Alcohol Services

    East Perth, Western Australia, 6004, Australia

  • Rankin Court Treatment Centre, St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, 2010, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.